SCHEDULE: Morgan Stanley Reduces Stake in AnaptysBio Below 5%
Beneficial Ownership Amendment
Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have reported reducing their beneficial ownership in AnaptysBio, Inc. to below the 5% threshold.
Summary
- Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, filed an Amendment No. 1 to Schedule 13G for ANAPTYSBIO, INC.
- Morgan Stanley reported beneficial ownership of 1,006,063 shares, representing 3.6% of ANAPTYSBIO, INC.'s Common Stock.
- Morgan Stanley Capital Services LLC reported beneficial ownership of 879,351 shares, representing 3.2% of ANAPTYSBIO, INC.'s Common Stock.
- Both entities have ceased to be beneficial owners of more than five percent of the class of securities as of the filing date.
- The filing indicates the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral disclosure, reflecting a routine change in institutional ownership rather than a direct commentary on the issuer's performance or prospects.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that a reduction in institutional ownership below the 5% threshold, as reported by Morgan Stanley, is a routine disclosure for large investment firms. While it indicates a decreased stake, it does not necessarily signal a negative outlook on AnaptysBio, Inc. but rather a portfolio rebalancing or a strategic adjustment in their investment allocation.
Related Party Transactions
- Morgan Stanley Capital Services LLC is a wholly-owned subsidiary of Morgan Stanley, and their beneficial ownership is reported collectively and individually, reflecting an internal organizational structure for investment management.
Stakeholder Impact
- Shareholders may note the reduced stake by a significant institutional investor, which could be interpreted in various ways, though the filing itself does not provide a rationale for the reduction. It primarily impacts transparency regarding major ownership positions.
Key Dates
| Date | Description |
|---|---|
| 12/31/2025 | Date of event which requires filing of this statement, indicating the reporting period end date for ownership status. |
| 02/11/2026 | Signing date of the Schedule 13G Amendment by Morgan Stanley and Morgan Stanley Capital Services LLC. |
Keywords
AnaptysBio, Morgan Stanley, Schedule 13G, beneficial ownership, common stock, institutional investment, stake reduction, biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.